Fusaricidin Antimicrobial Composition for Drug-Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifungal treatments are limited by high toxicity, poor efficacy, and resistance to development of resistance to treatment, and the emergence of antimicrobial resistance in pathogens poses a major threat to public health, with existing treatments failing to effectively combat drug-resistant pathogens.
Innovation Solution
Development of fusaricidin compositions derived from Paenibacillus or Bacillus bacteria, specifically cyclic and open-chain fusaricidin compounds, to treat a broad spectrum of infectious diseases, including those caused by drug-resistant pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antifungal treatments are used, then treatment of fungal infections is possible, but high toxicity and poor efficacy limit their use
Solution Approach 1:
The patent modifies the chemical structure of fusaricidin by changing amino acid residues at specific positions (e.g., X1-X6 in Formula I, X7-X12 in Formula II) to optimize the balance between antifungal efficacy and toxicity. This structural parameter modification allows retention of biological activity while reducing harmful effects on host cells.
Solution Approach 2:
The invention creates composite antifungal compositions by combining fusaricidin derivatives with other antifungal agents or adjuvants. This composite approach enhances overall efficacy while allowing lower doses of individual components, thereby reducing toxicity.
2Adaptability or versatility
If outdated therapeutics like colistin are used to treat ESKAPE pathogens, then treatment options are expanded, but toxicity increases and additional suffering is caused
Solution Approach 1:
The patent extracts and utilizes fusaricidin, a natural antimicrobial peptide produced by Paenibacillus and Bacillus bacteria, as an active ingredient. This extraction of a naturally occurring compound with broad-spectrum activity provides a new treatment option that avoids the toxicity problems of outdated therapeutics like colistin.
Solution Approach 2:
The invention employs fusaricidin derivatives that can be produced through fermentation processes using bacterial cultures. This approach provides a renewable, cost-effective source of antimicrobial agents that can be continuously produced to replace depleted or toxic traditional therapies.
3Adaptability or versatility
If fusaricidin compositions are used, then broad-spectrum antimicrobial activity is achieved, but new compound development is required
Solution Approach 1:
The patent segments the fusaricidin molecule into distinct functional regions (cyclic core structure with X1-X6 or X7-X12 amino acid positions, and side chain R1). This segmentation allows independent optimization of different regions to achieve broad-spectrum activity while maintaining manageable structural complexity.
Solution Approach 2:
The fusaricidin derivative structures described in the patent are designed to be universally active against multiple pathogen types including bacteria, fungi, and parasites. The core structural framework maintains broad-spectrum activity while allowing specific amino acid variations to target different microbial species.
Data Source
AI summary
Methods are provided for treating an infectious disease of a subject with a composition which comprises an active ingredient that can be produced by bacteria of Paenibacillus or Bacillus. The disclosure also provides a composition or a pharmaceutical composition which comprises, or alternatively consists essentially of, or yet further consists of an active ingredient which can be produced by bacteria of Paenibacillus or Bacillus.